Please assess the completion status of the following clinical trial:

Trial Title: Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed consent~* Confirmed COVID-19 (i.e. symptoms + positive test for SARS-CoV-2)~* Male or female, age ≥ 55 years~* At least two of the following additional risk factors:~Age ≥ 70 years Body mass index \> 25 kg/m2 Chronic obstructive pulmonary disease (COPD)\* Diabetes\* Cardiovascular disease\* Corticosteroid use~\*Defined as any disease requiring medical intervention or treatment.~Exclusion Criteria:~* Contraindications to unfractionated heparin or LMWH~* Recent (\<48 hours) or planned spinal or epidural anesthesia or puncture, PCI or thrombolytic therapy within the preceding 24 hours~* Increased risk for bleeding complications~* Pregnant women~* Severe renal impairment (GFR \< 30 mL/min)~* Receiving any antiplatelet therapy (with the exception of low dose (≤100mg) aspirin) or anticoagulant therapy (e.g. VKA, DOAC)~* Patients participating in an interventional study that is outside the purview of TRI sponsored studies.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: EXPERIMENTAL): (40 mg o/d if \< 100 kg, 40 mg b/d if ≥ 100 kg)
- Current standard of care (no enoxaparin) (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).